Delays in Initiation of Radiation Therapy after Breast Conserving Surgery May Explain Disparities in Breast Cancer Mortality among Older Women

Stephanie B. Wheeler, MPH, PhD

With Andrea K Biddle MPH PhD, William R Carpenter MHA PhD, Morris Weinberger PhD, Jeffrey Peppercorn MPH MD, Anna P Schenck PhD



Funding Acknowledgments


- National Research Service Award (NRSA) Predoctoral Traineeship from the Agency for Healthcare Research and Quality(AHRQ) sponsored by the Cecil G. Sheps Center for Health Services Research, UNC at Chapel Hill, Grant No. 5-T-32 HS000032-20 (PI: Carey)
- Grant No. 2KR50906 (PI: Wheeler) from the North Carolina Translational and Clinical Sciences (NC TraCS) Institute, Clinical and Translational Science Award (CTSA) Number UL1RR025747 from the National Center for Research Resources, NIH
- NCI RO1 award, Grant No. 5RO1CA124402-03 (PI: Weiner)
- Agency for Healthcare Research and Quality (AHRQ) ARRA Mentored Clinical Scientists Comparative Effectiveness Development Award (K12), Grant No. K-12 HS019468-01 (PI: Weinberger)

Background and Rationale

Racial Disparities in Breast Cancer

Rate per 100,000

- Black/white disparities in breast cancer outcomes well-documented
- Modest improvements in overall mortality over time, but the gap between races widening
 - Mammography receipt (Swan et al, 2003)
 - Stage at diagnosis (NCI, 2008)



interactive database (URL: http://www.seer.cancer.gov)

Does Treatment Timing Matter?

- Many potential explanations for racial disparities
- Differences in timing of radiation therapy (RT) after breast conserving surgery may account for some variation in outcomes
- Previous research on importance of RT timing conflicting (Gold et al., 2008; Hebert-Croteau et al., 2004; Hershman et al., 2006; Hickey et al., 2006; Hartsell et al., 1995; Tsoutsou et al., 2009) and limited by:
 - Incomplete assessment of all relevant time intervals
 - Focus on younger women
 - Failure to account for racial/ethnic variation
 - Failure to consider the role of other adjuvant therapy (e.g. chemo)
- Current quality metrics in breast cancer specify RT must be initiated within 1 year of diagnosis (ASCO/NCCN, 2008)

Research Objective

To examine racial/ethnic variation in timing of initiation of guideline-recommended radiation therapy (RT)* and its effect on all-cause and breast cancer-specific mortality

* Among Medicare-enrolled patients with stage I-III cancer who received breast conserving surgery (BCS)



Data and Population

- Linked Surveillance
 Epidemiology and End
 Results (SEER) Medicare
 dataset
- Female, communitydwelling, Medicare
 beneficiaries ages 65+
 who were diagnosed with
 primary breast cancer in
 SEER regions during 1994-2002



Exclusion Criteria

- Not enrolled in Parts A/B fee-for-service for the duration of the study period
- In situ or stage IV cancers
- ESRD
- Diagnosed at autopsy or death
- Other racial/ethnic groups (beyond non-Hispanic white, non-Hispanic black, and Hispanic)
- Did not receive BCS
- Additional cancer diagnosis within 1 year
- Starting sample = 254,803; final sample = 38,574

Analytic Methods

- Outcomes: All-cause and breast cancer-specific mortality
- Exposures: Race and timing of initiation of RT
 - RT timing: measured in months elapsed from diagnosis month to first indication of RT, determined by service dates in inpatient, outpatient, physician claims)
- Analysis: Multivariate logistic regression
 - Stratified by age and receipt of chemotherapy
 - Limited to women who received RT after BCS
- Covariates: Distance to nearest RT facility, distance traveled to surgery, timing of surgery, age at diagnosis, stage, grade, hormone receptor status, lymph node involvement, comorbidity burden, marital status, low income status (proxied using State-Buy-In), year of diagnosis, regional (zip code level) socioeconomic status



Descriptive Statistics, by Race

Patient-level variables	% or mean (SD) WHITE (N=34,965)	% or mean (SD) BLACK (N=2,273)	% or mean (SD) HISPANIC (N=1,336)
Age at diagnosis	75.7 (6.64)	75.2 (6.79)	74.4 (6.37)
Stage at diagnosis			
Stage I	64.47	52.35	56.44
Stage II	32.3	41.53	38.47
Stage III	3.23	6.12	5.09
Hormone receptor			
status			
ER positive	71.8	56.8	66.24
PR positive	59.02	45.18	54.27
Node positive	18.51	23.8	22.83
Co-morbidity	0.25 (0.46)	0.41 (0.61)	0.33 (0.53)
Chemo	19.91	24.34	23.16
Married	44.97	24.33	39.3
Low income	13.47	44.57	49.4


Notes: All racial differences were statistically significant at the p<0.05 level, as derived from chi-squared tests or ttests; ER: estrogen receptor; PR: progesterone receptor; RT: radiation therapy; SD: standard deviation

Bivariate Findings, by Race

Outcomes	White (N=34,965)	Black (N=2,273)	Hispanic (N=1,336)	p-value
% died within 5 yrs of diagnosis	22.2	30.5	22.7	<0.001
% died of breast cancer in 5 yrs	5.3	10.1	6.9	<0.001
Mean survival time (months)	60.0 (37.0)	53.4 (36.2)	56.7 (36.4)	<0.001~
				0.053#
Timing of RT initiation				
% ever received RT	58.2	51.4	58.3	<0.001
Mean RT initiation (months)	2.7 (2.9)	3.8 (3.5)	3.1 (3.0)	<0.001~
				<0.001#
% received in ≤6 mos.	90.9	82.2	87.5	
% received in >6 and ≤12 mos	7.4	14.8	10.7	<0.001
% received in >12 mos	1.7	2.9	1.8	

- By chemotherapy: median time to RT initiation was 2 months post-diagnosis among those who did not receive chemotherapy, whereas median time to RT initiation was 5 months post-diagnosis, among those who received chemotherapy.
- P-values from chi-squared and t-tests, as appropriate

Timing of initiation of RT among women who received BCS, by race/ethnicity (excluding women who received subsequent mastectomy during each time interval of interest)



Note: Y-error bars depict 95% confidence intervals

Odds ratios for effect of RT timing on mortality, conditioned <u>on receiving chemotherapy</u>

Independent Variable	65-69 yrs (N=1,762)		70 yrs+ (i	70 yrs+ (N=3,253)		
	All mortality	BrCa	All mortality	BrCa		
Timing of initiation of RT (≤1	month post-diagn	osis is referen	ce)			
>1 and ≤2 mos.	1.73+	1.56	1.21	0.97		
>2 and ≤3 mos.	0.66	0.68	1.05	0.74		
>3 and ≤4 mos.	0.53*	0.57	0.69+	0.97		
>4 and ≤5 mos.	0.61	0.70	0.73	0.95		
>5 and ≤6 mos.	0.49**	0.64	0.95	1.07		
>6 and ≤12 mos.	0.74	0.92	0.85	0.99		
>12 mos.	5.79**	6.58**	4.14**	5.04**		
Race/ethnicity (white is reference)						
Black	1.54	1.97*	1.24	1.38		
Hispanic	1.21	0.85	1.28	1.58		

Notes: + significant at 10%; * significant at 5%; ** significant at 1%; ORs for control variables not shown

- More advanced stage disease associated with greater all-cause and BrCa mortality
- Being ER or PR positive associated with lower all cause and BrCa mortality
- Higher co-morbidity associated with greater all-cause mortality

Odds ratios for effect of RT timing on mortality, conditioned <u>on not receiving chemotherapy</u>

Independent Variable	65-69 yrs (N=3,320)		70 yrs +(N=12,184)		
	All mortality	BrCa	All mortality	BrCa	
Timing of initiation of RT (≤	1 month post-diag	nosis is refere	ence)		
>1 and ≤2 mos.	1.19	1.36	0.99	0.98	
>2 and ≤3 mos.	1.10	0.66	0.93	0.91	
>3 and ≤4 mos.	0.64	1.18	1.28+	1.51	
>4 and ≤5 mos.	2.95*	1.05	0.94	1.33	
>5 and ≤6 mos.	4.85*	1.00		1.52	
<u>>6 and ≤12 mos.</u>	1.85	2.16	2.80**	7.35**	
>12 mos.	6.54**	13.04**	3.88**	6.31**	
Race/ethnicity (white is reference)					
Black	0.68	1.78	1.01	0.86	
Hispanic	0.63	2.39	0.87	1.09	

Notes: + significant at 10%; * significant at 5%; ** significant at 1%; ORs for control variables not shown

- More advanced stage disease associated with greater all-cause and BrCa mortality
- Higher co-morbidity associated with greater all-cause mortality
- Marital status associated with protective effect against mortality for 70+ population

Limitations

- Limited generalizability
- Difficult to determine where "things went wrong"...
- Possible endogeneity/unmeasured confounding
 - Propensity to initiate RT early may be related to unmeasurable functional/health status
 - No info on endocrine therapy (no Part D)
 - Burden of seeking care/traveling for appointments

Conclusions

- Black women experience greater mortality and live about 6 months less than white women
- Black and Hispanic women experience more treatment delays
- In multivariate models controlling for timing of RT and other covariates, the effect of race is no longer significant
- Across all models, receipt of RT more than 1 year post-diagnosis was strongly associated with higher odds of all-cause and breast cancerspecific mortality
 - Among women ages 65-69 who <u>did not receive chemotherapy</u>, initiating RT more than <u>4 months</u> post-diagnosis associated with higher odds of all-cause mortality
 - Among women ages 70 and older who <u>did not receive chemotherapy</u>, initiating RT more than <u>6 months</u> post-diagnosis associated with higher odds of all-cause and breast cancer-specific mortality
- Black women are diagnosed later and have clinically poorer prognosis based upon biological tumor features
 - Therefore, if timing does matter, it is precisely this group of women who should receive care as early as possible



Independent Variable 65-69 years old (N=1762) 70 years and older (N=3253) lity

Odds ratios for the effect of timing of RT	on mortality, conditioned on receiving	g adjuvant chemotherapy, stratified by age group

	All-cause mortality	BrCa mortality	All-cause mortality	BrCa mortality
Timing of initiation of RT (<=1 month post-diagnosis is referen	nce)			
>1 and <=2 mos.	1.73+	1.56	1.21	0.97
>2 and <=3 mos.	0.66	0.68	1.05	0.74
>3 and <=4 mos.	0.53*	0.57	0.69+	0.97
>4 and <=5 mos.	0.61	0.70	0.73	0.95
>5 and <=6 mos.	0.49**	0.64	0.95	1.07
>6 and <=12 mos.	0.74	0.92	0.85	0.99
>12 mos.	5.79**	6.58**	4.14**	5.04**
Race/ethnicity (white is reference)				
Black	1.54	1.97*	1.24	1.38
Hispanic	1.21	0.85	1.28	1.58
Covariates				
Age (grouped in 5-year categories; 70-74 years is reference)				
75-79 years	-	-	1.49**	1.38*
80-84 years	-	-	2.01**	1.54*
85 years and older	-	-	2.43**	1.36
Received surgery in diagnosis month	1.45*	2.40**	1.09	1.2
Stage at diagnosis (stage I is reference)				
Stage II	1.83**	2.29**	1.73**	2.20**
Stage III	5.32**	6.55**	4.35**	5.84**
Grade (well-differentiated is reference)	0.02	0.00		0101
Moderately-differentiated	1.89*	3.04*	1.06	1.49
Poorly-differentiated	3.02**	6.45**	1.51**	2.59**
			1.4	2.39
Anaplastic	2.63	5.73*		
Grade missing	2.27*	5.72**	1.05	1.61
Hormone receptor status (negative, borderline, or unknown is	,			
ER positive	0.68+	0.66	0.81+	0.69*
PR positive	0.75	0.58+	0.77*	0.63**
Node status (node negative is reference)				
Node positive	1.15	1.01	1.06	1.31
Node status missing	1.86*	1.34	1.87**	1.16
Co-morbidity index (score of 0 is reference)				
0.01-1	1.39+	0.81	1.53**	1.16
1.01-2	3.06**	2.50*	2.84**	1.35
> 2	2.24	1.28	3.43**	0.63
Married	0.8	1.02	0.91	0.87
Low income proxy (State-Buy-In)	1.19	1.53	0.91	0.88
Year of diagnosis (1994 is reference)				
1995	0.84	0.87	0.53*	0.54*
1996	1.02	1.36	0.46**	0.49*
1997	1.29	1.33	0.52*	0.53*
1998	0.75	0.90	0.40**	0.30**
1999	0.88	1.08	0.49**	0.37**
2000	0.49+	0.62	0.44**	0.31**
2001	0.71	0.66	0.41**	0.24**
2002	0.56	0.47	0.27**	0.19**

Independent Variable	65-69 years o All-cause mortality		70 years and old All-cause mortality	
Timing of initiation of RT (<=1 month post-diagnosis is reference		Broa montanty		Broatmont
>1 and <=2 mos.	, 1.19	1.36	0.99	0.98
>2 and <=3 mos.	1.10	0.66	0.93	0.91
>3 and <=4 mos	0.64	1.18	1.28+	1.51
>4 and <=5 mos.	2.95*	1.05	0.94	1.33
>5 and <=6 mos.	4.85*	#	1.22	1.53
>6 and <=12 mos.	1.85	2.16	2.80**	7.35**
>12 mos.	6.54**	13.04**	3.88**	6.31**
Race/ethnicity (white is reference)	0101		0100	0.0.1
Black	0.68	1.78	1.01	0.86
Hispanic	0.63	2.39	0.87	1.09
Covariates				
Age (grouped in 5-year categories; 70-74 years is reference)				
75-79 years	-	-	1.27**	1.05
80-84 years	-	-	1.99**	1.41*
85 years and older	-	-	3.35**	1.3
Received surgery in diagnosis month	1.17	0.96	0.93	0.9
Stage at diagnosis (stage I is reference)				
Stage II	1.67*	2.37*	1.50**	2.98**
Stage III	3.89*	2.77	3.29**	6.32**
Grade (well-differentiated is reference)		o / -		0.0=++
Moderately-differentiated	1.14	2.15	1.26**	2.27**
Poorly-differentiated	1.52+	3.67**	1.66**	4.75**
Anaplastic	4.02**	7.19*	1.25	5.10**
Grade missing	0.9	0.84	1.25*	2.52**
Hormone receptor status (negative, borderline, or unknown is		a a=		
ER positive	0.99	0.67	0.88	0.61**
PR positive	1.04	1.27	0.95	1.03
Node status (node negative is reference)	1.60+	1.83	1.27*	1.62**
Node positive Node status missing	1.62*	0.95	1.58**	2.14**
-	1.02	0.95	1.50	2.14
Co-morbidity index (score of 0 is reference)	0.40**		0.00**	4.05
0.01-1	2.43**	1.44	2.02**	1.05
1.01-2 > 2	5.94** 11.39**	2.00 4.70	3.38** 10.06**	1.36 3.14**
Married	0.97	0.88	0.87*	0.76*
Low income proxy (State-Buy-In)	1.29	0.88	1.06	0.76
Year of diagnosis (1994 is reference)	1.29	0.7	1.00	0.0
1995	0.65	0.81	0.82	0.72
1996	0.47*	0.39	0.70**	0.63*
1997	0.71	1.05	0.76*	0.60*
1998	1.0	0.79	0.70	0.80
1999	0.64	0.95	0.74*	0.81
2000	0.81	1.0	0.74	0.78
2001	0.61	1.01	0.81+	0.59*
2002	0.73	0.10+	0.72*	0.50**

Odds ratios for the effect of timing of RT on mortality, conditioned on not receiving chemotherapy, stratified by age group

Measurement: health care services

Treatment	Primary means of identification
Diagnostic codes	174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9 Other: V10.3
Aggressive surgery	ICD9CM procedure: 85.41, 85.42, 85.43, 85.44, 85.45, 85.46, 85.47, 85.48 CPT/HCPCS: 19180, 19182 , 19200, 19220, 19240 , 19260-19272, 19303-19307
BCS	ICD9CM procedure: 85.20, 85.21, 85.22, 85.23, 85.24, 85.25 CPT/HCPCS: 19120, 19125, 19126, 19160, 19162, 19301, 19302
Radiation therapy	ICD9CM procedure: 92.21-92.29 CPT/HCPCS: 77261-77499 , 77520, 77522, 77523, 77525, 77750-77799, G0256, G0261 Revenue Center Code: 0330, 0333 , 0339 DRG: 409 Other: V58.0, V66.1, V67.1

First or only primary breast cancer cases from SEER areas diagnosed in 1994+, female only, N=254,803

